Navigation Links
Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
Date:5/28/2009

MOUNTAIN VIEW, Calif., May 28 /PRNewswire/ -- Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., today announced the upcoming (June 1, 2009) release of the Xfect(TM) and Xfect(TM) Stem transfection reagents. These novel transfection reagents are based on biodegradable nanoparticles that permit superior transfection efficiency of plasmid DNA into mammalian cells. For added ease of use, transfections can be carried out entirely in the presence of serum. Xfect shows high efficiency over a broad range of cell types, while Xfect Stem meets the highly specialized requirements for mouse embryonic stem cell transfections.

Carol Lou, General Manager of Clontech Laboratories, Inc., comments: "Clontech has a long history of leadership in developing technologies for gene delivery and expression. We identified a need for cost-effective, efficient and non-toxic transfection reagents, and responded with an innovative solution. We are pleased to announce the addition of Xfect transfection reagents to our wide range of established products, including our Lenti-X(TM) and Adeno-X(TM) viral delivery systems and vectors for Tet-On(R) Advanced- and ProteoTuner(TM)-based inducible expression."

Researchers recognize that effective, nontoxic DNA transfer is a vital first step in basic and applied research, including studies of gene regulation, protein expression, and function; the development of transgenic organisms; and therapeutic gene delivery. Clontech has a patent license from M.I.T. based on research by scientists at M.I.T. who screened more than 2,300 candidate polymers to identify novel biodegradable nanoparticles that facilitate exceptional transfection efficiency. Under the license, Clontech optimized two of the lead compounds from the screen to create the Xfect and Xfect Stem reagents.

About Clontech Laboratories, Inc.

Clontech Laboratories, Inc., a wholly-owned subsidiary of Takara Bio Inc., develops, manufactures, and distributes a wide range of life science research reagents under the Clontech and Takara brands. Key products include high-performance qPCR and PCR reagents (including the Ex Taq(TM), LA Taq(TM), Titanium(TM), and Advantage(R) enzymes); RT enzymes and SMART(TM) library construction kits; the innovative In-Fusion(TM) cloning system; Tet-based inducible gene expression systems; and a range of Macherey-Nagel nucleic acid purification tools. These and other products support applications including gene discovery, regulation, and function; protein expression and purification; RNAi and stem cell studies; and plant and food research. For more information visit www.clontech.com.

About Takara Bio Inc.

Takara Bio Inc. is an innovative biotechnology company based in Shiga, Japan. As a world leader in biotechnology research and development, Takara Bio was the first company to market PCR technology in Japan and is also the developer of the RetroNectin(R) reagent, which is a world-standard in gene therapy protocols. In addition to providing research reagents and equipment to the life science research market, Takara Bio has active research and product development activities in the fields of gene and cell-based therapy, and agricultural biotechnology; and is committed to preventing disease and improving the quality of life for all people through the use of biotechnology. Through strategic alliances with other industry leaders, the Company aims to extend its reach around the world. More information is available at http://www.takara-bio.com.


'/>"/>
SOURCE Clontech Laboratories, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Clontech Laboratories, Inc. Releases the ProteoTuner(TM) Systems
2. Clontech Laboratories, Inc. Recognizes the 2008 Winners of the Nobel Prize in Chemistry
3. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Methimazole Tablets USP, 5 mg and 10 mg
4. Forest Laboratories, Inc. and Merz Pharma GmbH & Co. KgaA File Additional Lawsuit Against Several Companies for Patent Infringement
5. Forest Laboratories, Inc. Announces Positive Results of Memantine Study of Once-Daily Formulation
6. Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement
7. Forest Laboratories, Inc. and Daiichi Sankyo, Inc. Announce the Termination of the AZOR Co-Promotion Agreement
8. Forest Laboratories, Inc. and Laboratorios Almirall, S.A. to Host Webcast to Discuss Aclidinium Bromide Data Presentations at the American Thoracic Society Annual Congress
9. Forest Laboratories, Inc. Sets Date and Conference Call for Fiscal 2009 First Quarter Earnings
10. Caraco Pharmaceutical Laboratories, Ltd. Announces Resignation from Board of Directors of Jitendra Doshi and Appointment of GP Singh Sachdeva
11. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the First Quarter of Fiscal Year 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... ... March 22, 2017 , ... ... regeneration from small lab samples to full-size tissues, bones, even whole organs to ... vascular system that delivers blood deep into the developing tissue. , Current ...
(Date:3/22/2017)... Good Start Genetics, a leading family genomics ... million covered lives mark through its most recent payor ... . With newly signed contracts nationally and others ... payor acceptance based on the quality of its science, ... its industry-leading customer care and support and its published ...
(Date:3/22/2017)... 2017 The global chronic kidney ... report by Transparency Market Research (TMR). The top four ... AbbVie Inc., accounted for a share of only 41.4% ... this market are focusing aggressively on mergers, acquisitions, and ... likely to lead to market consolidation in the next ...
(Date:3/22/2017)... 22, 2017   Boston Biomedical , an industry ... to target cancer stemness pathways, today announced its Board ... as Chief Executive Officer, effective April 24, 2017. ... Li , M.D., FACP, who has led Boston Biomedical ... his leadership, Boston Biomedical has grown from a "garage ...
Breaking Biology Technology:
(Date:3/9/2017)... VIEW, Calif. , March 9, 2017 ... 23andMe , the leading personal genetics company, are using ... now provide customers with personalized nutrition plans that consider ... but also genetic markers impacting how their body may ... food decision support platform uses biometrics such as Body ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
(Date:3/1/2017)... , March 1, 2017  Aware, Inc. (NASDAQ: ... announced that Richard P. Moberg has resigned, ... co-President and Chief Financial Officer and Treasurer of Aware ... to serve as a member of the Board of ... , Aware,s co-Chief Executive Officer and co-President, General Counsel ...
Breaking Biology News(10 mins):